Sunitinib Versus Placebo for Patients with Advanced Unresectable Pancreatic Neuroendocrine Tumors
0 विचारों
• 07/09/23
0
0
एम्बेड
administrator
ग्राहकों
From ASCO 2011 -- A discussion with Prof. Eric Raymond on his poster presented at ASCO in June 2011 titled "Updated Overall Survival (OS) and Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) of Sunitinib Versus Placebo for Patients with Advanced Unresectable Pancreatic Neuroendocrine Tumors (NET)"
और दिखाओ
फेसबुक टिप्पणियाँ
SORT BY-
सबसे ऊपर की टिप्पणी
-
नवीनतम टिप्पणियां